ClinicalTrials.gg
TerminatedNCT05603143BIRCHUpdated Dec 20, 2024Results posted

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

A Phase 3 interventional study of Obeldesivir and Obeldesivir Placebo in COVID-19, sponsored by Gilead Sciences. Terminated at 81 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the low number of events.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in COVID-19 by Gilead Sciences — none open to participants now, none under way, none of them phase 3. COVID-19 · Gilead Sciences.

Started
2022
the only one that year
Phase 3
6 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in COVID-19 by Gilead Sciences, this one is the only one that started in 2022, is one of 6 in phase 3, and was the 8th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 10 studies in COVID-19 by Gilead Sciences is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in COVID-19 by Gilead Sciences as a file.
02

Study summary

The goal of this clinical study is to test how well the study drug, obeldesivir (GS-5245), works and how safe it is in treating coronavirus disease 2019 (COVID-19) in participants that have a higher risk of getting a serious illness.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Willing and able to provide written .
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by PCR or an approved alternative assay (eg. Rapid Antigen Test) ≤ 5 days before randomization. Serologic tests will not be accepted.
  • Initial onset of COVID-19 signs/symptoms ≤ 5 days before randomization.
  • Not currently hospitalized or requiring hospitalization.
  • Presence of ≥ 1 risk factor (if unvaccinated) or ≥ 2 risk factors (if vaccinated at any point) for progression to severe disease.

Key Exclusion Criteria:

  • Anticipated use of COVID-19 therapies during the current COVID-19 illness.
  • Received any direct acting antiviral drug against SARS-CoV-2 for the treatment of COVID-19 \< 28 days or \< 5 half-lives, whichever is longer, before randomization.
  • Anticipated need for hospitalization \< 48 hours after randomization.
  • New oxygen requirement \< 24 hours before randomization.
  • Decompensated cirrhosis ( class B or C) or acute liver injury/failure.
  • Undergoing dialysis, or history of moderate to severe renal impairment.
  • Pregnant or breastfeeding (nursing).
  • Unwilling to use protocol-mandated .
  • Received an approved, authorized or COVID-19 vaccine (including booster dose) \<120 days before randomization.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
468 participants (actual)

Study arms

  • Experimental
    Obeldesivir

    Participants will receive obeldesivir 350 mg orally twice daily for 5 days.

    Drug: Obeldesivir

  • Placebo comparator
    Placebo

    Participants will receive placebo-to-match obeldesivir orally twice daily for 5 days.

    Drug: Obeldesivir Placebo

Interventions

  • Tablets administered orally without regard to food.

    Also known as: GS-5245

  • DrugObeldesivir Placebo

    Placebo tablets administered orally without regard to food.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization or All-Cause Death by Day 29

    COVID-19-related hospitalization was defined as ≥ 24 hours of acute care for a reason related to COVID-19, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This included specialized acute medical care units within an assisted living facility or nursing home. This did not include hospitalization for the purposes of public health and/or clinical trial execution. The date and duration of hospital admission, and primary reason for hospitalization (including if the hospitalization was related to COVID-19) were recorded. Percentages were rounded off.

    Time frame: Up to Day 29

Secondary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)

    TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. Any AEs leading to premature discontinuation of study drug. Percentages were rounded off.

    Time frame: First dose date up to 5 Days plus 30 Days

  2. Percentage of Participants Experiencing Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Percentages were rounded off.

    Time frame: First dose date up to 5 Days plus 30 Days

  3. Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation

    A treatment emergent AE is defined as an AE that occurs or worsens in severity on or after the date of the first dose of study drug but no later than 30 days after the permanent discontinuation of study drug or an AE leading to discontinuation of study drug. A SAE is defined as an event that, at any dose, resulted in any of the following: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. Percentages were rounded off.

    Time frame: First dose date up to 5 Days plus 30 Days

  4. Percentage of Participants With All-Cause Hospitalization by Day 29

    All-cause hospitalization was defined as ≥ 24 hours of acute care, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This includes specialized acute medical care units within an assisted living facility or nursing home. This does not include hospitalization for the purposes of public health and/or clinical study execution. The date and duration of hospital admission, and primary reason for hospitalization (including if the hospitalization is related to COVID-19) were recorded. Percentages were rounded off.

    Time frame: Up to Day 29

  5. Percentage of Participants With COVID-19-Related Medically Attended Visits (MAVs) or All-Cause Death by Day 29

    Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.

    Time frame: Up to Day 29

  6. Percentage of Participants With COVID-19-Related MAVs by Day 29

    Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.

    Time frame: Up to Day 29

  7. Percentage of Participants With All-cause Death by Day 29

    Percentages were rounded off.

    Time frame: Up to Day 29

  8. Time to COVID-19 Symptom Alleviation by Day 15

    Time to COVID-19 symptom alleviation was calculated as symptom alleviation date/time minus the first dose date/time. Symptom alleviation was evaluated for the 15 targeted symptoms using symptoms of infection with coronavirus-19 (SIC) questionnaire. The SIC questionnaire assessed all targeted symptoms, alleviation was defined as the SIC rating of 0, or at least 3 points decrease in rating from baseline, or an answer "No" to the question for at least 48 consecutive hours.

    Time frame: Up to Day 15

  9. Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5

    The mixed model for repeated measures (MMRM) was used for analysis.

    Time frame: Day 5

  10. Plasma Concentrations of GS-441524 (Metabolite of Obeldesivir)

    Time frame: Day 1, 0.75 and 2 hours postdose and Day 5 predose and 0.75 hours postdose

07

Results

Posted Dec 20, 2024

Participant flow

Participants were enrolled at study sites in the South America, Europe, North America, Africa and Asia.

Participant flow — Overall Study
MilestoneObeldesivirPlacebo
Started233235
Completed224227
Not completed98
Withdrew: Withdrew consent62
Withdrew: Randomized but never treated03
Withdrew: Adverse event20
Withdrew: Death01
Withdrew: Investigator's discretion10
Withdrew: Lost to follow-up01
Withdrew: Protocol violation01

Outcome measures

PrimaryPercentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization or All-Cause Death by Day 29

COVID-19-related hospitalization was defined as ≥ 24 hours of acute care for a reason related to COVID-19, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This included specialized acute medical care units within an assisted living facility or nursing home. This did not include hospitalization for the purposes of public health and/or clinical trial execution. The date and duration of hospital admission, and primary reason for hospitalization (including if the hospitalization was related to COVID-19) were recorded. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization or All-Cause Death by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization or All-Cause Death by Day 2900.5
Statistical analysis
  • Obeldesivir vs Placebo · Log Rank · p = 0.3161
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAE)

TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. Any AEs leading to premature discontinuation of study drug. Percentages were rounded off.

Time frame:
First dose date up to 5 Days plus 30 Days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)
percentage of participantsObeldesivirPlacebo
Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)22.220.8
SecondaryPercentage of Participants Experiencing Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Percentages were rounded off.

Time frame:
First dose date up to 5 Days plus 30 Days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Laboratory Abnormalities
percentage of participantsObeldesivirPlacebo
Any grade56.161.7
Grade 3 or 46.54.8
SecondaryPercentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation

A treatment emergent AE is defined as an AE that occurs or worsens in severity on or after the date of the first dose of study drug but no later than 30 days after the permanent discontinuation of study drug or an AE leading to discontinuation of study drug. A SAE is defined as an event that, at any dose, resulted in any of the following: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. Percentages were rounded off.

Time frame:
First dose date up to 5 Days plus 30 Days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation
percentage of participantsObeldesivirPlacebo
AEs Leading to Study Drug Discontinuation1.70.9
SAEs Leading to Study Drug Discontinuation0.90.9
SecondaryPercentage of Participants With All-Cause Hospitalization by Day 29

All-cause hospitalization was defined as ≥ 24 hours of acute care, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This includes specialized acute medical care units within an assisted living facility or nursing home. This does not include hospitalization for the purposes of public health and/or clinical study execution. The date and duration of hospital admission, and primary reason for hospitalization (including if the hospitalization is related to COVID-19) were recorded. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With All-Cause Hospitalization by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With All-Cause Hospitalization by Day 290.50
Statistical analysis
  • Obeldesivir vs Placebo · Log Rank · p = 0.3219
SecondaryPercentage of Participants With COVID-19-Related Medically Attended Visits (MAVs) or All-Cause Death by Day 29

Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19-Related Medically Attended Visits (MAVs) or All-Cause Death by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With COVID-19-Related Medically Attended Visits (MAVs) or All-Cause Death by Day 291.01.0
Statistical analysis
  • Obeldesivir vs Placebo · Log Rank · p = 0.6568 · Hazard ratio (hr): 1.496 · 95% CI 0.250 to 8.952Hazard ratio and two-sided 95% CI for hazard ratio were estimated using the Cox regression.
SecondaryPercentage of Participants With COVID-19-Related MAVs by Day 29

Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19-Related MAVs by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With COVID-19-Related MAVs by Day 2910.5
Statistical analysis
  • Obeldesivir vs Placebo · Log Rank · p = 0.3190 · Hazard ratio (hr): 2.990 · 95% CI 0.311 to 28.740Hazard ratio and two-sided 95% CI for hazard ratio were estimated using the Cox regression.
SecondaryPercentage of Participants With All-cause Death by Day 29

Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With All-cause Death by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With All-cause Death by Day 2900.5
Statistical analysis
  • Obeldesivir vs Placebo · Log Rank · p = 0.3161
SecondaryTime to COVID-19 Symptom Alleviation by Day 15

Time to COVID-19 symptom alleviation was calculated as symptom alleviation date/time minus the first dose date/time. Symptom alleviation was evaluated for the 15 targeted symptoms using symptoms of infection with coronavirus-19 (SIC) questionnaire. The SIC questionnaire assessed all targeted symptoms, alleviation was defined as the SIC rating of 0, or at least 3 points decrease in rating from baseline, or an answer "No" to the question for at least 48 consecutive hours.

Time frame:
Up to Day 15
Reported as:
Median · Days
Time to COVID-19 Symptom Alleviation by Day 15
DaysObeldesivirPlacebo
Time to COVID-19 Symptom Alleviation by Day 157.3 (5.4 to 9.4)9.3 (6.5 to NA)
Statistical analysis
  • Obeldesivir vs Placebo · Log Rank · p = 0.0859 (P-value was based on stratified Log-rank test with randomization stratification factors as the strata.) · Hazard ratio (hr): 1.425 · 95% CI 0.961 to 2.112Hazard ratio and two-sided 95% CI for hazard ratio were estimated using the Cox regression with randomization stratification factors as covariates.
SecondaryChange From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5

The mixed model for repeated measures (MMRM) was used for analysis.

Time frame:
Day 5
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5
log10 copies/mLObeldesivirPlacebo
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5-2.80 ± 0.092-2.22 ± 0.092
Statistical analysis
  • Obeldesivir vs Placebo · MMRM · p = < 0.0001 · Treatment difference (vs placebo): -0.58 · 95% CI -0.83 to -0.33Least-squares mean (SE), 95% CI and P value were from MMRM with baseline viral load and randomization strata as covariates.
SecondaryPlasma Concentrations of GS-441524 (Metabolite of Obeldesivir)
Time frame:
Day 1, 0.75 and 2 hours postdose and Day 5 predose and 0.75 hours postdose
Reported as:
Mean · ng/mL
Plasma Concentrations of GS-441524 (Metabolite of Obeldesivir)
ng/mLObeldesivir
Day 1, 0.75 hours postdose2330.42 ± 1709.560
Day 1, 2 hours postdose2535.84 ± 1370.131
Day 5, Predose1116.81 ± 1101.371
Day 5, 0.75 hours postdose3089.09 ± 1839.992

Adverse events

Collected over All-cause mortality, Adverse events: First dose date up to 5 Days plus 30 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obeldesivir0/234 (0%)2/234 (0.9%)0/234 (0%)
Placebo1/234 (0.4%)2/231 (0.9%)0/231 (0%)
Most frequent serious events
Most frequent serious events
EventObeldesivirPlacebo
VomitingGastrointestinal disorders0/2341/231
DeathGeneral disorders0/2341/231
DizzinessNervous system disorders1/2340/231
DyspnoeaRespiratory, thoracic and mediastinal disorders1/2340/231

Baseline characteristics

The All Randomized Analysis Set included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(years)ObeldesivirPlaceboTotal
Mean57 ± 14.953 ± 16.655 ± 15.8
Age, Customized
Age, Customized(Participants)ObeldesivirPlaceboTotal
Adults (18 - 64 Years)159173332
Geriatrics (65 - 84 Years)7159130
Geriatrics (85 Years and Over)336
Sex: Female, Male
Sex: Female, Male(Participants)ObeldesivirPlaceboTotal
Female147117264
Male86118204
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ObeldesivirPlaceboTotal
Hispanic or Latino364379
Not Hispanic or Latino197192389
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ObeldesivirPlaceboTotal
White178168346
Asian243256
American Indian or Alaska Native211940
Black or African American91019
Other or More Than One Race145
Native Hawaiian or Other Pacific Islander022
Region of Enrollment
Region of Enrollment(Participants)ObeldesivirPlaceboTotal
Romania292453
Singapore101
Hungary011
Japan235
United Kingdom808
Portugal459
Spain111223
Canada71118
South Korea123
Turkey112
Taiwan172340
Brazil358
Poland12719
Italy112
Mexico242448
South Africa151631
Bulgaria9799196
France011
Baseline Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load
Baseline Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load(log10 copies/mL)ObeldesivirPlaceboTotal
Mean6.15 ± 1.6296.15 ± 1.6226.15 ± 1.624
08

Study locations

81 sites
  • Faculdade de Medicina da Universidade Federal de Minas Gerais
    Belo Horizonte - MG, 30130-100, Brazil
  • L2iP Instituto de Pesquisas Clínicas
    Brasília - DF, 70200-730, Brazil
  • Centro de Pesquisa Clinica da Universidade Municipal de São Caetano do Sul (USCS)
    São Caetano Do Sul - SP, 09530-905, Brazil
  • Multiprofile Hospital for Active Treatment Puls AD, Department of Internal Diseases
    Blagoevgrad, 2700, Bulgaria
  • Medical Center Asklepii OOD
    Dupnitsa, 2600, Bulgaria
  • Specialìzed Hosp¡tal for Active Trealment of Pneumophthisiatric Diseases Haskovo EOOD, Department of pneumology and phthisiatry
    Haskovo, 6300, Bulgaria
  • Medical Center Zdrave-1 OOD
    Kozloduy, 3320, Bulgaria
  • Diagnostic Consultative Center 1 - Lon EOOD
    Lom, 3600, Bulgaria
  • Medical Center Hera EOOD, Montana
    Montana, 3400, Bulgaria
  • Multiprofile Hospital for Active Treatment Dr. Stamen Iliev AD, Department of Pneumology Phthisiatrics
    Montana, 3400, Bulgaria
  • Medical Center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
  • Diagnostic Consultative Center Sveti Georgi EOOD
    Plovdiv, 4000, Bulgaria
  • MHAT Sveta Karidad EAD, First Department of Anesthesiology and Intensive Care
    Plovdiv, 4004, Bulgaria
  • Multiprofile Hospital for Active Treatment Sveti Panteleymon EOOD, First Department of Internal Diseases
    Plovdiv, 4004, Bulgaria
  • Medical Center Prolet EOOD
    Ruse, 7002, Bulgaria
  • Multiprofile Hospital for Active Treatment - Samokov EOOD, Department of Internal Diseases
    Samokov, 2000, Bulgaria
  • Medical Center Unimed EOOD
    Sevlievo, 5400, Bulgaria
  • Diagnostic and Consulting Center Aleksandrovska EOOD
    Sofia, 1431, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • Diagnostic Consultative Center XX - Sofia EOOD
    Sofia, 1618, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases-Vratsa EOOD, Department of Pneumology
    Vratsa, 3000, Bulgaria
  • Hamilton Medical Research Group
    Hamilton, L8M 1K7, Canada
  • Dr. Anil K. Gupta Medicine Professional Corporation
    Toronto, M9V 4B4, Canada
  • Vancouver ID Research and Care Centre Society
    Vancouver, V6Z 2C9, Canada
  • CHU de Montpellier-Hopital La Colombiere
    Montpellier, 34090, France
  • Hopital Pitie Salpetriere
    Paris Cedex 13, 75651, France
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4031, Hungary
  • Unita Operativa Di Malattie Infettive Ospedale San Raffaele S.r.l.
    Milano, 20127, Italy
  • IUHW Narita Hospital
    Chibaken, 286-0124, Japan
  • Okayama University Hospital
    Okayama, 700-8558, Japan
  • Suita Municipal Hospital
    Suita, 564-8567, Japan
  • ChungNam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Chonnam National University Bitgoeul Hospital
    Gwangju, 61748, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 152-703, Korea, Republic of
  • Panamerican Clinical Research Mexico S.A. de C.V.
    Col. El Salitre Juriquilla, 13030, Mexico
  • Neurociencias Estudios Clinicos S.C.
    Culiacan Sinaloa, 80020, Mexico
  • PanAmerican Clinical Research Mexico S.A de C.V.
    Guadalajara, 44670, Mexico
  • EME RED Hospitalaria
    Merida, 97000, Mexico
  • Clinstile, S.A. De C.V.
    Mexico City, 06700, Mexico
  • Kohler & Milstein Research S.A de C.V.
    Mérida, 97070, Mexico
  • Oaxaca Site Management Organization S.C.
    Oaxaca, 68000, Mexico
  • FAICIC S. de R.L. de C.V.
    Veracruz, 91900, Mexico
  • ClinMedica Research
    Skierniewice, Lodzkie 96-100, Poland
  • Ginemedica OVO 21
    Wroclaw, 50414, Poland
  • ETG Lodz
    Zgierz, 95-100, Poland
  • Hospital CUF Descobertas
    Lisboa, 1998-018, Portugal
  • Centro Hospitalar de Entre Douro e Vouga - Hospital de Sao Sebaststiao
    Santa Maria da Feira, 4520-211, Portugal
  • Hospital da Luz - Arrabida
    Vila Nova de Gaia, 4099-346, Portugal
  • "Prof. Dr. Matei Bals" National Institute for Infectious Diseases
    Bucharest, 021105, Romania
  • County Hospital Caracal
    Caracal, 235200, Romania
  • Sibiu Emergency Clinical County Hospital
    Sibiu, 550253, Romania
  • National Centre for Infectious Diseases, Tan Tock Seng Hospital
    Singapore, 308433, Singapore
  • Madibeng Centre for Research
    Brits, 0250, South Africa
  • Clinresco Centres (Pty) Ltd
    City Of Johannesburg, 1619, South Africa
  • Synapta Clinical Research Centre
    Durban, 4001, South Africa
  • Perinatal HIV Research Unit (PHRU)
    Johannesburg, 2013, South Africa
  • Jongaie Research
    Pretoria West, 0183, South Africa
  • Global Clinical Trials
    Pretoria, 0001, South Africa
  • Limpopo Clinical Research Initiative
    Thabazimbi, 0380, South Africa
  • FCRN Clinical Trial Centre (Pty) Ltd
    Vereeniging, 1938, South Africa
  • Hospital Universitario Virgen de Las Nieves.
    a Gudiña, 32540, Spain
  • Hospital General Universitario Dr. Balmis
    Alicante, 3010, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona, 08916, Spain
  • CAP La Mina
    Barcelona, 8007, Spain
  • Hospital HM Nou Delfos
    Barcelona, 8023, Spain
  • Hospital Universitario Virgen del Rocio
    las Cabezas de San Juan, 41730, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Majadahonda, 28222, Spain
  • Hospital General Universitario Reina Sofia
    Murcia, 30003, Spain
  • Hospital Universitario Son Espases
    Palma de Mallorca, 07120, Spain
  • Hospital Universitaro y Politecnico La Fe
    Valencia, 46016, Spain
  • Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
    Hualien City, 970, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Taiwan University Hospital
    Taipei City, 100, Taiwan
  • Tao-Yuan General Hospital
    Taoyuan City, 320, Taiwan
  • Kaohsiung Veterans General Hospital
    Zuo Ying Qu, 813, Taiwan
  • Acibadem University School of Medicine Atakent Hospital
    Trabzon, 61030, Turkey
  • Ormeau Clinical Trials Limited
    Belfast, BT7 2EB, United Kingdom
  • Lakeside Healthcare
    Corby, NN17 2UR, United Kingdom
  • CPS Research
    Glasgow, G20 0XA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Nov 2023, 12 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2022
First posted
Nov 2, 2022
StartActual
Nov 5, 2022
Primary completionActual
Nov 7, 2023
CompletionActual
Nov 7, 2023
Results first posted
Dec 20, 2024
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05603143
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 2, 2022
Start date
Nov 5, 2022
Primary completion
Nov 7, 2023
Completion
Nov 7, 2023
Results posted
Dec 20, 2024
Last update
Dec 20, 2024

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obeldesivir

Start the discussion